Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
DIABETES OBESITY & METABOLISM
Volume 20, Issue 4, Pages 910-920
Publisher
Wiley
Online
2017-11-30
DOI
10.1111/dom.13177
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China
- (2017) Fiona Bragg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer
- (2016) A. Blythe Ryerson et al. CANCER
- Hyperglycemia, tumorigenesis, and chronic inflammation
- (2016) Shu-Chun Chang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Use of incretin agents and risk of pancreatic cancer: a population-based cohort study
- (2016) L. M. Knapen et al. DIABETES OBESITY & METABOLISM
- GLP-1 action attenuates breast cancer growth and progression
- (2016) Shiho komatsu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
- (2016) Laurent Azoulay et al. BMJ-British Medical Journal
- Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
- (2015) Michael Roden et al. Cardiovascular Diabetology
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
- (2015) Francesco Giorgino et al. DIABETES CARE
- Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes
- (2015) Andrew Lewin et al. DIABETES CARE
- Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
- (2015) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial
- (2015) S. C. L. Gough et al. DIABETES OBESITY & METABOLISM
- Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes
- (2015) Chin-Hsiao Tseng EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
- (2015) Lawrence Blonde et al. LANCET
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner
- (2014) Hejun Zhao et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The Human GLP-1 Analogs Liraglutide and Semaglutide: Absence of Histopathological Effects on the Pancreas in Nonhuman Primates
- (2014) C. F. Gotfredsen et al. DIABETES
- Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin
- (2014) Itamar Raz et al. DIABETES CARE
- Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
- (2014) Julio Rosenstock et al. DIABETES CARE
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
- (2014) Guillermo Umpierrez et al. DIABETES CARE
- Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study
- (2014) M. Gokhale et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
- (2014) P. D. Home et al. DIABETES OBESITY & METABOLISM
- Activation of glucagon-like peptide-1 receptor inhibits tumourigenicity and metastasis of human pancreatic cancer cells via PI3K/Akt pathway
- (2014) H. Zhao et al. DIABETES OBESITY & METABOLISM
- HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
- (2014) Peter N. Weissman et al. DIABETOLOGIA
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
- (2014) L. Li et al. BMJ-British Medical Journal
- Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study
- (2014) J.-L. Faillie et al. BMJ-British Medical Journal
- One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
- (2013) Kathryn Aston-Mourney et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
- (2013) A. E. Butler et al. DIABETES
- Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study
- (2013) H. Yki-Jarvinen et al. DIABETES CARE
- Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes
- (2013) N. Inagaki et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone-a factorial study
- (2013) R. R. Henry et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study
- (2013) T. Haak et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial
- (2013) Burkhard Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exendin-4 Induces Cell Adhesion and Differentiation and Counteracts the Invasive Potential of Human Neuroblastoma Cells
- (2013) Paola Luciani et al. PLoS One
- Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus
- (2013) Sonal Singh et al. JAMA Internal Medicine
- Pancreatitis and incretin-based drugs: clarity or confusion?
- (2013) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study
- (2013) Carlo B Giorda et al. Lancet Diabetes & Endocrinology
- Impact of Tumor Progression on Cancer Incidence Curves
- (2012) E. G. Luebeck et al. CANCER RESEARCH
- Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12DMouse Model
- (2012) Belinda Gier et al. DIABETES
- The Human GLP-1 Analog Liraglutide and the Pancreas
- (2012) Niels C.B. Nyborg et al. DIABETES
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population
- (2012) John A. Romley et al. Diabetes Technology & Therapeutics
- Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
- (2012) Baptist Gallwitz et al. LANCET
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells
- (2011) Hagai Ligumsky et al. BREAST CANCER RESEARCH AND TREATMENT
- Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
- (2011) Antonio R Chacra et al. Diabetes & Vascular Disease Research
- Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
- (2011) Priscilla L Hollander et al. Diabetes & Vascular Disease Research
- Glucagon-Like Peptide-1 Receptor Activation Inhibits Growth and Augments Apoptosis in Murine CT26 Colon Cancer Cells
- (2011) Jacqueline A. Koehler et al. ENDOCRINOLOGY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
- (2010) T. Seck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
- (2009) J. S. Nachnani et al. DIABETOLOGIA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now